Movement Alert｜Guardant Health Inc. Rises 6.33% in After-Hours Trading, Q2 Revenue Beats Expectations and Full-Year Guidance Raised

Market Focus07-31

On July 31, Guardant Health Inc. rose 6.33% in after-hours trading, trading at $163.5/share, with turnover of $35.02 million. The surge was driven by the company's Q2 earnings release, which featured revenue significantly above consensus and an upward revision to full-year guidance.

Guardant Health reported Q2 revenue of $335.0 million, up 44.3% year-over-year, comfortably beating the analyst consensus estimate of $314.2 million. Adjusted loss per share came in at $0.42, narrowing from $0.44 in the prior-year quarter. The company raised its full-year revenue outlook to $1.34 billion–$1.36 billion, up from $1.30 billion–$1.32 billion previously, surpassing the FactSet estimate of $1.31 billion.

The strong results come amid multiple recent catalysts, including FDA approval of Guardant360 Liquid CDx as a companion diagnostic for non-small cell lung cancer therapy, inclusion of the Shield blood test in American Cancer Society colorectal screening guidelines, and several analyst target price increases from institutions including BofA Securities and RBC Capital Markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178629036?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-31 05:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178629036","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Guardant Health Inc. Rises 6.33% in After-Hours Trading, Q2 Revenue Beats Expectations and Full-Year Guidance Raised","media":"Market Focus","content":"<p><p>On July 31, Guardant Health Inc. rose 6.33% in after-hours trading, trading at $163.5/share, with turnover of $35.02 million. The surge was driven by the company's Q2 earnings release, which featured revenue significantly above consensus and an upward revision to full-year guidance.</p><p>Guardant Health reported Q2 revenue of $335.0 million, up 44.3% year-over-year, comfortably beating the analyst consensus estimate of $314.2 million. Adjusted loss per share came in at $0.42, narrowing from $0.44 in the prior-year quarter. The company raised its full-year revenue outlook to $1.34 billion–$1.36 billion, up from $1.30 billion–$1.32 billion previously, surpassing the FactSet estimate of $1.31 billion.</p><p>The strong results come amid multiple recent catalysts, including FDA approval of Guardant360 Liquid CDx as a companion diagnostic for non-small cell lung cancer therapy, inclusion of the Shield blood test in American Cancer Society colorectal screening guidelines, and several analyst target price increases from institutions including BofA Securities and RBC Capital Markets.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Guardant Health Inc. Rises 6.33% in After-Hours Trading, Q2 Revenue Beats Expectations and Full-Year Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Guardant Health Inc. Rises 6.33% in After-Hours Trading, Q2 Revenue Beats Expectations and Full-Year Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-31 05:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 31, Guardant Health Inc. rose 6.33% in after-hours trading, trading at $163.5/share, with turnover of $35.02 million. The surge was driven by the company's Q2 earnings release, which featured revenue significantly above consensus and an upward revision to full-year guidance.</p><p>Guardant Health reported Q2 revenue of $335.0 million, up 44.3% year-over-year, comfortably beating the analyst consensus estimate of $314.2 million. Adjusted loss per share came in at $0.42, narrowing from $0.44 in the prior-year quarter. The company raised its full-year revenue outlook to $1.34 billion–$1.36 billion, up from $1.30 billion–$1.32 billion previously, surpassing the FactSet estimate of $1.31 billion.</p><p>The strong results come amid multiple recent catalysts, including FDA approval of Guardant360 Liquid CDx as a companion diagnostic for non-small cell lung cancer therapy, inclusion of the Shield blood test in American Cancer Society colorectal screening guidelines, and several analyst target price increases from institutions including BofA Securities and RBC Capital Markets.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1178629036","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178629036","pubTimestamp":1785448631,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 31, Guardant Health Inc. rose 6.33% in after-hours trading, trading at $163.5/share, with turnover of $35.02 million. The surge was driven by the company's Q2 earnings release, which featured...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"走势警报|Guardant Health Inc. 盘后交易中上涨 6.33%，第二季度收入超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"On July 31, Guardant Health Inc. rose 6.33% in after-hours trading, trading at $163.5/share, with turnover of $35.02 million. The surge was driven by the company's Q2 earnings release, which featured revenue significantly above consensus and an upward revision to full-year guidance.Guardant Health reported Q2 revenue of $335.0 million, up 44.3% year-over-year, comfortably beating the analyst consensus estimate of $314.2 million. Adjusted loss per share came in at $0.42, narrowing from $0.44 in the prior-year quarter. The company raised its full-year revenue outlook to $1.34 billion–$1.36 billion, up from $1.30 billion–$1.32 billion previously, surpassing the FactSet estimate of $1.31 billion.The strong results come amid multiple recent catalysts, including FDA approval of Guardant360 Liquid CDx as a companion diagnostic for non-small cell lung cancer therapy, inclusion of the Shield blood test in American Cancer Society colorectal screening guidelines, and several analyst target price increases from institutions including BofA Securities and RBC Capital Markets.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178629036","isCrawlerRequest":true}